NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $19.95 +0.26 (+1.34%) As of 01:02 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Replimune Group Stock (NASDAQ:REPL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Replimune Group alerts:Sign Up Key Stats Today's Range$19.33▼$20.1250-Day Range$10.86▼$23.2852-Week Range$1.50▼$23.54Volume768,628 shsAverage Volume4.27 million shsMarket Capitalization$1.89 billionP/E RatioN/ADividend YieldN/APrice Target$18.17Consensus RatingModerate Buy Company Overview Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies. Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.AI Generated. May Contain Errors. Read More Replimune Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreREPL MarketRank™: 1.43369175627 of 5 starsReplimune Group scored higher than 29% of companies evaluated by MarketBeat, and ranked 752nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingReplimune Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.Downside RiskReplimune Group has a consensus price target of $18.17, representing about 8.6% downside from its current price of $19.88.Amount of Analyst CoverageReplimune Group has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Replimune Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($2.40) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -7.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 9.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.44% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 8.31.Change versus previous monthShort interest in Replimune Group has recently increased by 6.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.50 News SentimentReplimune Group has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Replimune Group this week, compared to 6 articles on an average week.Search Interest6 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $521,860.00 in company stock.Percentage Held by Insiders5.40% of the stock of Replimune Group is held by insiders.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPL Stock News HeadlinesReplimune Earnings Call Highlights Rapid TUDRIQEV LaunchNovember 17 at 5:59 AM | theglobeandmail.comReplimune Group (NASDAQ:REPL) Stock Falls 4.8% After Insider SellingNovember 13, 2026 | americanbankingnews.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.November 18 at 1:00 AM | Profits Run (Ad)Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit BuyingNovember 11, 2026 | benzinga.comInsider Selling: Replimune Group (NASDAQ:REPL) Director Sells $113,360.00 in StockNovember 11, 2026 | insidertrades.comReplimune Group, Inc. (REPL) - What Are Analysts Saying About This Stock?November 7, 2026 | americanbankingnews.comHow Investors May Respond To Replimune Group (REPL) Narrower Quarterly LossNovember 5, 2026 | finance.yahoo.comCramer's lightning round: Buy FedEx FreightNovember 3, 2026 | msn.comSee More Headlines REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $9.72 at the beginning of the year. Since then, REPL stock has increased by 104.5% and is now trading at $19.88. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Wednesday, October, 28th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24. Read the conference call transcript. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional shareholders of Replimune Group include State Street Corp (4.40%), Marshall Wace LLP (4.02%), Goldman Sachs Group Inc. (3.50%) and Jump Financial LLC (0.52%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Sushil Patel, Konstantinos Xynos, Emily Luisa Hill, Christopher Sarchi, Andrew Schwendenman, Kapil Dhingra and Joseph P Slattery. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Palantir Technologies (PLTR), Marvell Technology (MRVL), Micron Technology (MU), Regeneron Pharmaceuticals (REGN), Archer Aviation (ACHR), Amprius Technologies (AMPX) and Chevron (CVX). Company Calendar Last Earnings10/28/2026Today11/18/2026Next Earnings (Estimated)2/02/2027Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 REPL's financial health is in the Green zone, according to TradeSmith. REPL has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:REPL CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees465Year Founded2015Price Target and Rating Average Price Target for Replimune Group$18.17 High Price Target$31.00 Low Price Target$2.00 Potential Upside/Downside-8.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$313.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-157.78% Return on Assets-83.89% Debt Debt-to-Equity Ratio0.59 Current Ratio7.11 Quick Ratio6.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book9.20Miscellaneous Outstanding Shares94,800,000Free Float89,681,000Market Cap$1.88 billion OptionableOptionable Beta0.93 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:REPL) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.